TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04827056

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PTSD Reactivity Condition
Description: Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Cue Reactivity
Description: Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Cue Reactivity
Description: Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Cue Reactivity
Description: Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
Study: NCT05203939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU400 Med Dose
Description: subretinal injection of upto 3.33 × 10\^10 vg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU400 Med Dose
Description: subretinal injection of upto 3.33 × 10\^10 vg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU400 High Dose
Description: subretinal injection of upto 1.66 × 10\^11 vg/mL
Study: NCT06309810

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral~1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs).
Study: NCT06567561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Foods Plant-Based Diet
Description: Whole foods, predominantly plant-based diet, with the addition of fish, eggs, and fermented dairy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Firehouse Diet
Description: Usual firehouse meals.
Study: NCT04945343

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Growing Rods
Description: Growing Rods(GR), are implants used to correct pediatric scoliosis deformity. They attempt to allow the growth of the spine and thorax while controlling curve progression to preserve normal lung volume.
Study: NCT04280471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsule
Description: Receive OpenBiome FMT Capsule DE PO
Study: NCT06242340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm group bathing 24 hours after birth.
Description: Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm group bathing 48 hours after birth.
Description: Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early term group bathing 24 hours after birth.
Description: Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early term group bathing 48 hours after birth.
Description: Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
Study: NCT06221735

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cy-TB test
Description: The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cy-TB test
Description: The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cy-TB test
Description: The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: STANDARD F TB-Feron FIA test
Description: The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD F TB-Feron FIA test
Description: The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: STANDARD F TB-Feron FIA test
Description: The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
Study: NCT04420780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of sugar-free gums sugar-free gums containing 100% Xylitol as sweetener
Description: The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Administration of sugar-free gums sugar-free gums containing containing a polyols mixture plus a low amount of Xylitol (22%)
Description: The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
Study: NCT04373668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night Time Care Activities Programme
Description: Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
Study: NCT04941313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D229
Description: 3D229 is an investigational drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D229
Description: 3D229 is an investigational drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05717790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab
Description: Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
Study: NCT06225245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Stimulation (ESS)
Description: ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) \[31-33\]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
Study: NCT05762458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine
Description: Ammoxetine hydrochloride enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine
Description: Ammoxetine hydrochloride enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to Ammoxetine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to Ammoxetine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to Ammoxetine.
Study: NCT04668820

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: video Pediatric Gait, Arms, Legs and Spine (V-pGALS)
Description: The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
Study: NCT05757830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UANGO suite exoskeleton
Description: Each subject will perform 3 experimental conditions (Condition 1: Walking without exoskeleton; Condition 2: Walking with exoskeleton; Condition 3: Walking with exoskeleton and walker).~Each condition includes 5 triasl (Trial 1 - Sitting: 5 minutes, sitting at rest in comfortable position; Trial 2 - Standing: 5 minutes, with assistance; Trial 3 - Comfortable speed Walking (100% assisted): 4 min during back-and-forth locomotion on a 20-m length linear flat path; Trial 4 - Comfortable speed Walking (75% assistance): 4 min during back-and-forth locomotion on a 20-m length linear flat path, Trial 4 is not available in condition 1; Trial 5 - 1 minute Sit to stand test). Nasa TLX and RPE will be requested at the end of each trial. Usability questionnaires will be fullfilled at the end of condition 2 and condition 3.
Study: NCT06442228

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spermiogram test
Description: Approximately 7 mL of blood sample will be taken by the health personnel in a vacuum gel tube for hormonal and biochemical analyses. The blood samples will be centrifuged at 1000xg for 20 minutes by the researchers. In the next step, the supernatant portion will be separated and transferred to 3 mL ependorfs. Serum samples will be stored in the -800C deep freezer of our hospital until the time of analysis.~Sperm samples from individuals will be collected in our hospital in accordance with the protocol and the results will be reported.
Study: NCT04980170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg
Description: patients will be given clindamycin 300 mg twice daily for 5 days after dental implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin with Clavulanic Acid 635mg
Description: patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
Study: NCT06042296

Intervention type: OTHER
Intervention: Expression of CD44, E-cadherin and PCNA
Description: The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)

Intervention type: OTHER
Intervention: Expression of CD44, E-cadherin and PCNA
Description: The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)

Intervention type: OTHER
Intervention: Expression of CD44, E-cadherin and PCNA
Description: The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
Study: NCT05580510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG OD
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG OD
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug.
Study: NCT06287125

Intervention type: DEVICE
Intervention: Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147
Description: Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI

Intervention type: DEVICE
Intervention: Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147
Description: Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI
Study: NCT05449574

Intervention type: DIAGNOSTIC_TEST
Intervention: Scale for the Assessment of Sensory Integration in Adults
Description: In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
Study: NCT06287125

Intervention type: DEVICE
Intervention: Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147
Description: Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI
Study: NCT06174558

Intervention type: DEVICE
Intervention: Sleep Tracking Devices
Description: Observational Study, Smartwatches and home sleep device for sleep and respiratory monitoring
Study: NCT05997030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low intensity focused ultrasound (LIFU)
Description: Subjects will undergo undergo a single LIFU of the target brain region
Study: NCT04949737

Intervention type: BIOLOGICAL
Intervention: Helicobacter Pylori detection
Description: Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire.
Study: NCT04696848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-516 plus Durvalumab
Description: Stage 1 : dose escalation durvalumab (1500 mg Q4W) in combination with CKD-516 at 1 of 3 planned dose levels (9, 11, or 13 mg/m2 twice a week for 3 weeks in each cycle, Q4W).~Stage 2 : durvalumab (1500 mg Q4W) in combination with CKD-516 at recommended phase 2 dose (twice a week for 3 weeks in each cycle, Q4W).
Study: NCT05898737

Intervention type: DEVICE
Intervention: NOL-Index
Description: NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
Study: NCT06022874

Intervention type: OTHER
Intervention: Phoilex Releaf Gel
Description: Patients will be given the Releaf Gel to apply to the affected areas daily. They will be examined at the following time points: Immediately after application, 1 week, 2 weeks, and 4 weeks.~The instructions given to the patient shall be to apply one pump per every affected area, wash hands before applying to affected area, apply twice a day (morning, and evening), apply on clean skin, and application after showering is advised.~The number of pumps of Phoilex Releaf gel will be documented within a chart provided to the patient. It is suggested that not more than 25 lesions compassing an area greater than 50 cm² in total be treated during the course of this study.~The maximum dose would be 240 mL of Phoilex Releaf gel in 30 days. The minimum dose would be 0.5 mL (one pump) of the Phoilex Releaf gel in 30 days. The maximum daily dose of CBD per day 46 mg per application, equivalent to 92 mg per day.